Targeting the pancreatic β-cell to treat diabetes

Nature Reviews Drug Discovery

Volumn 13, Issue 4, 2014, Pages 278-289

  Vetere, Amedeo ^a   Choudhary, Amit ^a,b   Burns, Sean M ^a   Wagner, Bridget K ^a  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BROMOCRIPTINE; CYCLIN DEPENDENT KINASE 6; CYTOKINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 120; G PROTEIN COUPLED RECEPTOR 40; GIVINOSTAT; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOKINASE; HISTONE DEACETYLASE INHIBITOR; INCRETIN; INSULIN DERIVATIVE; MEGLITINIDE; METFORMIN; MICRORNA; NATURAL PRODUCT; PLANT EXTRACT; PRAMLINTIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRANSCRIPTION FACTOR PAX4; TRANSCRIPTION FACTOR PDX 1; TRICHOSTATIN A; VORINOSTAT;

AGING; APOPTOSIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; DIABETES MELLITUS; DRUG SCREENING; DRUG TARGETING; GENETIC ASSOCIATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LINKAGE ANALYSIS; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MOLECULAR TARGETED THERAPY;

EID: 84898598784     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4231     Document Type: Review

References (177)

1. Ashcroft, F. M. & Rorsman, P. Diabetes mellitus and the beta cell: the last ten years. Cell 148, 1160-1171 (2012).
2. Bluestone, J. A., Herold, K. & Eisenbarth, G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464, 1293-1300 (2010).
3. Butler, A. E. et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102-110 (2003).
4. Ferrannini, E. The stunned beta cell: a brief history. Cell. Metab. 11, 349-352 (2010).
5. Samuel, V. T. & Shulman, G. I. Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852-871 (2012).
6. Talchai, C., Lin, H. V., Kitamura, T. & Accili, D. Genetic and biochemical pathways of beta-cell failure in type 2 diabetes. Diabetes Obes. Metab. 11 (Suppl. 4), 38-45 (2009).
7. Dupuis, J. et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature Genet. 42, 105-116 (2010).
8. Scott, R. A. et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nature Genet. 44, 991-1005 (2012).
9. Sladek, R. et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445, 881-885 (2007).
10. Strawbridge, R. J. et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes 60, 2624-2634 (2011).
11. Meier, J. J. et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 57, 1584-1594 (2008).
12. Papa, F. R. Endoplasmic reticulum stress, pancreatic beta-cell degeneration, and diabetes. Cold Spring Harb. Perspect. Med. 2, a007666 (2012).
13. Eizirik, D. L. & Darville, M. I. Beta-cell apoptosis and defense mechanisms: lessons from type 1 diabetes. Diabetes 50 (Suppl. 1), 64-69 (2001).
14. Collombat, P. et al. The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently β cells. Cell 138, 449-462 (2009).
15. Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J. & Melton, D. A. In vivo reprogramming of adult pancreatic exocrine cells to β-cells. Nature 455, 627-632 (2008).
16. Juhl, C. B. et al. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes. Diabetes 50, 1778-1784 (2001).
17. Reers, C. et al. Impaired islet turnover in human donor pancreata with aging. Eur. J. Endocrinol. 160, 185-191 (2009).
18. Keenan, H. A. et al. Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 59, 2846-2853 (2010).
19. Cozar-Castellano, I. et al. Molecular control of cell cycle progression in the pancreatic β-cell. Endocr. Rev. 27, 356-370 (2006).
20. Heit, J. J., Karnik, S. K. & Kim, S. K. Intrinsic regulators of pancreatic β-cell proliferation. Annu. Rev. Cell Dev. Biol. 22, 311-338 (2006).
21. Lee, Y. C. & Nielsen, J. H. Regulation of beta cell replication. Mol. Cell Endocrinol. 297, 18-27 (2009).
22. Krishnamurthy, J. et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 443, 453-457 (2006).
23. Kohler, C. U. et al. Cell cycle control of β-cell replication in the prenatal and postnatal human pancreas. Am. J. Physiol. Endocrinol. Metab. 300, E221-E230 (2011).
24. Georgia, S. & Bhushan, A. p27 regulates the transition of β-cells from quiescence to proliferation. Diabetes 55, 2950-2956 (2006).
25. Kushner, J. A. et al. Cyclins D2 and D1 are essential for postnatal pancreatic β-cell growth. Mol. Cell. Biol. 25, 3752-3762 (2005).
26. Fiaschi-Taesch, N. M. et al. Induction of human β-cell proliferation and engraftment using a single G1/S regulatory molecule, cdk6. Diabetes 59, 1926-1936 (2010).
27. Fiaschi-Taesch, N. M. et al. Human pancreatic β-cell G1/S molecule cell cycle atlas. Diabetes 62, 2450-2459 (2013).
28. Fiaschi-Taesch, N. M. et al. Cytoplasmic-nuclear trafficking of G1/S cell cycle molecules and adult human β-cell replication: a revised model of human beta-cell G1/S control. Diabetes 62, 2460-2470 (2013).
29. Rieck, S. & Kaestner, K. H. Expansion of β-cell mass in response to pregnancy. Trends Endocrinol. Metab. 21, 151-158 (2010).
30. Parsons, J. A., Brelje, T. C. & Sorenson, R. L. Adaptation of islets of Langerhans to pregnancy: increased islet cell proliferation and insulin secretion correlates with the onset of placental lactogen secretion. Endocrinology 130, 1459-1466 (1992).
31. Chen, G. et al. Molecular mechanism of pancreatic β-cell adaptive proliferation: studies during pregnancy in rats and in vitro. Endocrine 39, 118-127 (2011).
32. Tamura, K. et al. Stress response gene ATF3 is a target of c-myc in serum-induced cell proliferation. EMBO J. 24, 2590-2601 (2005).
33. Kim, H. et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nature Med. 16, 804-808 (2010).
34. Gylfe, E. Serotonin as marker for the secretory granules in the pancreatic beta-cell. Acta Physiol. Scand. Suppl. 452, 125-128 (1977).
35. Butler, A. E. et al. Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy. Diabetologia 53, 2167-2176 (2010).
36. Michael, M. D. et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 6, 87-97 (2000).
37. El Ouaamari, A. et al. Liver-derived systemic factors drive β cell hyperplasia in insulin-resistant states. Cell Rep. 3, 401-410 (2013).
38. Salpeter, S. J. et al. Systemic regulation of the age-related decline of pancreatic β-cell replication. Diabetes 62, 2843-2848 (2013).
39. Yi, P., Park, J. S. & Melton, D. A. Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell 153, 747-758 (2013).
40. Chen, H. et al. Polycomb protein Ezh2 regulates pancreatic β-cell Ink4a/Arf expression and regeneration in diabetes mellitus. Genes Dev. 23, 975-985 (2009).
41. Zeng, N. et al. Pten controls β-cell regeneration in aged mice by regulating cell cycle inhibitor p16ink4a. Aging Cell 12, 1000-1011 (2013).
42. Bernal-Mizrachi, E. et al. Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet β cells. J. Clin. Invest. 114, 928-936 (2004).
43. Holst, L. S. et al. Protein kinase B is expressed in pancreatic β cells and activated upon stimulation with insulin-like growth factor I. Biochem. Biophys. Res. Commun. 250, 181-186 (1998).
44. Liu, W., Chin-Chance, C., Lee, E. J. & Lowe, W. L. Jr. Activation of phosphatidylinositol 3-kinase contributes to insulin-like growth factor I-mediated inhibition of pancreatic ß-cell death. Endocrinology 143, 3802-3812 (2002).
45. Tuttle, R. L. et al. Regulation of pancreatic ß-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nature Med. 7, 1133-1137 (2001).
46. Vetere, A. & Wagner, B. K. Chemical methods to induce beta-cell proliferation. Int. J. Endocrinol. 2012, 925143 (2012).
47. Shen, W. et al. Small-molecule inducer of ß cell proliferation identified by high-throughput screening. J. Am. Chem. Soc. 135, 1669-1672 (2013).
48. Annes, J. P. et al. Adenosine kinase inhibition selectively promotes rodent and porcine islet ß-cell replication. Proc. Natl Acad. Sci. USA 109, 3915-3920 (2012).
49. Andersson, O. et al. Adenosine signaling promotes regeneration of pancreatic ß cells in vivo. Cell. Metab. 15, 885-894 (2012).
50. Oh, S. M. et al. Ebp1 sumoylation, regulated by TLS/FUS E3 ligase, is required for its anti-proliferative activity. Oncogene 29, 1017-1030 (2010).
51. Squatrito, M., Mancino, M., Donzelli, M., Areces, L. B. & Draetta, G. F. EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes. Oncogene 23, 4454-4465 (2004).
52. Andres, C. M. & Fox, I. H. Purification and properties of human placental adenosine kinase. J. Biol. Chem. 254, 11388-11393 (1979).
53. Rovira, M. et al. Chemical screen identifies FDAapproved drugs and target pathways that induce precocious pancreatic endocrine differentiation. Proc. Natl Acad. Sci. USA 108, 19264-19269 (2011).
54. Jacovetti, C. et al. MicroRNAs contribute to compensatory ß cell expansion during pregnancy and obesity. J. Clin. Invest. 122, 3541-3551 (2012).
55. Lynn, F. C. et al. MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes 56, 2938-2945 (2007).
56. Joglekar, M. V., Joglekar, V. M. & Hardikar, A. A. Expression of islet-specific microRNAs during human pancreatic development. Gene Expr. Patterns 9, 109-113 (2009).
57. Poy, M. N. et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432, 226-230 (2004).
58. Guay, C., Roggli, E., Nesca, V., Jacovetti, C. & Regazzi, R. Diabetes mellitus, a microRNA-related disease? Transl. Res. 157, 253-264 (2011).
59. Lovis, P., Gattesco, S. & Regazzi, R. Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by microRNAs. Biol. Chem. 389, 305-312 (2008).
60. Wang, Y., Liu, J., Liu, C., Naji, A. & Stoffers, D. A. MicroRNA-7 regulates the mTOR pathway and proliferation in adult pancreatic ß-cells. Diabetes 62, 887-895 (2013).
61. Bravo-Egana, V. et al. Quantitative differential expression analysis reveals miR-7 as major islet microRNA. Biochem. Biophys. Res. Commun. 366, 922-926 (2008).
62. Correa-Medina, M. et al. MicroRNA miR-7 is preferentially expressed in endocrine cells of the developing and adult human pancreas. Gene Expr. Patterns 9, 193-199 (2009).
63. van de Bunt, M. et al. The miRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis. PLoS ONE 8, e55272 (2013).
64. Chaparro, R. J., Burton, A. R., Serreze, D. V., Vignali, D. A. & DiLorenzo, T. P. Rapid identification of MHC class I-restricted antigens relevant to autoimmune diabetes using retrogenic T cells. J. Immunol. Methods 335, 106-115 (2008).
65. DiLorenzo, T. P. & Serreze, D. V. The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice. Immunol. Rev. 204, 250-263 (2005).
66. Concannon, P., Rich, S. S. & Nepom, G. T. Genetics of type 1A diabetes. N. Engl. J. Med. 360, 1646-1654 (2009).
67. Santin, I. & Eizirik, D. L. Candidate genes for type 1 diabetes modulate pancreatic islet inflammation and beta-cell apoptosis. Diabetes Obes. Metab. 15 (Suppl. 3), 71-81 (2013).
68. Cardozo, A. K. et al. IL-1ß and IFN-. induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia 46, 255-266 (2003).
69. Pearl-Yafe, M. et al. Pancreatic islets under attack: cellular and molecular effectors. Curr. Pharm. Des. 13, 749-760 (2007).
70. Yoon, J. W. & Jun, H. S. Autoimmune destruction of pancreatic beta cells. Am. J. Ther. 12, 580-591 (2005).
71. Bobbala, D. et al. Interleukin-15 plays an essential role in the pathogenesis of autoimmune diabetes in the NOD mouse. Diabetologia 55, 3010-3020 (2012).
72. Monti, P. et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J. Clin. Invest. 118, 1806-1814 (2008).
73. Varanasi, V., Avanesyan, L., Schumann, D. M. & Chervonsky, A. V. Cytotoxic mechanisms employed by mouse T cells to destroy pancreatic ß-cells. Diabetes 61, 2862-2870 (2012).
74. Thomas, H. E., Trapani, J. A. & Kay, T. W. The role of perforin and granzymes in diabetes. Cell Death Differ. 17, 577-585 (2010).
75. Eizirik, D. L. & Mandrup-Poulsen, T. A choice of death-the signal-transduction of immune-mediated ß-cell apoptosis. Diabetologia 44, 2115-2133 (2001).
76. Allison, J., Thomas, H. E., Catterall, T., Kay, T. W. & Strasser, A. Transgenic expression of dominantnegative Fas-associated death domain protein in ß cells protects against Fas ligand-induced apoptosis and reduces spontaneous diabetes in nonobese diabetic mice. J. Immunol. 175, 293-301 (2005).
77. Kawasaki, E., Abiru, N. & Eguchi, K. Prevention of type 1 diabetes: from the view point of beta cell damage. Diabetes Res. Clin. Pract. 66 (Suppl. 1), 27-32 (2004).
78. McKenzie, M. D. et al. Proapoptotic BH3-only protein Bid is essential for death receptor-induced apoptosis of pancreatic ß-cells. Diabetes 57, 1284-1292 (2008).
79. Cardozo, A. K. et al. A comprehensive analysis of cytokine-induced and nuclear factor-.B-dependent genes in primary rat pancreatic ß-cells. J. Biol. Chem. 276, 48879-48886 (2001).
80. Cnop, M. et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54 (Suppl. 2), 97-107 (2005).
81. Moore, F. et al. STAT1 is a master regulator of pancreatic ß-cell apoptosis and islet inflammation. J. Biol. Chem. 286, 929-941 (2011).
82. Barthson, J. et al. Tumor necrosis factor-a and interferon-. induce pancreatic ß-cell apoptosis through STAT1-mediated Bim activation. J. Biol. Chem. 286, 39632-39643 (2011).
83. Ortis, F. et al. Induction of nuclear factor-.B and its downstream genes by TNF-a and IL-1ß has a proapoptotic role in pancreatic ß cells. Diabetologia 51, 1213-1225 (2008).
84. Holohan, C., Szegezdi, E., Ritter, T., O'Brien, T. & Samali, A. Cytokine-induced ß-cell apoptosis is NO-dependent, mitochondria-mediated and inhibited by BCL-XL. J. Cell. Mol. Med. 12, 591-606 (2008).
85. Eldor, R. et al. Conditional and specific NF-.B blockade protects pancreatic ß cells from diabetogenic agents. Proc. Natl Acad. Sci. USA 103, 5072-5077 (2006).
86. Lee, J. H. et al. Overexpression of SIRT1 protects pancreatic ß-cells against cytokine toxicity by suppressing the nuclear factor-.B signaling pathway. Diabetes 58, 344-351 (2009).
87. Callewaert, H. I. et al. Deletion of STAT-1 pancreatic islets protects against streptozotocin-induced diabetes and early graft failure but not against late rejection. Diabetes 56, 2169-2173 (2007).
88. Kim, E. K. et al. Inhibitory effect of Artemisia capillaris extract on cytokine-induced nitric oxide formation and cytotoxicity of RINm5F cells. Int. J. Mol. Med. 19, 535-540 (2007).
89. Kim, E. K. et al. Coptidis rhizoma extract protects against cytokine-induced death of pancreatic ß-cells through suppression of NF-.B activation. Exp. Mol. Med. 39, 149-159 (2007).
90. Menegazzi, M. et al. Protective effects of St. John's wort extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic ß-cell line. Int. J. Biochem. Cell Biol. 40, 1509-1521 (2008).
91. Song, M. Y. et al. Radix asari extract protects pancreatic ß cells against cytokine-induced toxicity: implication of the NF-.B-iNOS signaling cascade. Int. J. Mol. Med. 20, 769-775 (2007).
92. Bonny, C., Oberson, A., Negri, S., Sauser, C. & Schorderet, D. F. Cell-permeable peptide inhibitors of JNK: novel blockers of ß-cell death. Diabetes 50, 77-82 (2001).
93. Ablamunits, V. et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 61, 145-154 (2012).
94. Sandberg, J. O., Andersson, A., Eizirik, D. L. & Sandler, S. Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem. Biophys. Res. Commun. 202, 543-548 (1994).
95. Moran, A. et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381, 1905-1915 (2013).
96. Cavelti-Weder, C. et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35, 1654-1662 (2012).
97. Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007).
98. Sloan-Lancaster, J. et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1ß antibody, in patients with type 2 diabetes. Diabetes Care 36, 2239-2246 (2013).
99. Larsen, L. et al. Inhibition of histone deacetylases prevents cytokine-induced toxicity in ß cells. Diabetologia 50, 779-789 (2007).
100. Lewis, E. C. et al. The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet ß-cells in vivo and in vitro. Mol. Med. 17, 369-377 (2010).
101. Patel, T., Patel, V., Singh, R. & Jayaraman, S. Chromatin remodeling resets the immune system to protect against autoimmune diabetes in mice. Immunol. Cell Biol. 89, 640-649 (2011).
102. Chou, D. H. et al. Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis. Chem. Biol. 19, 669-673 (2012).
103. Lundh, M. et al. Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children. Diabetologia 55, 2421-2431 (2012).
104. Chou, D. H. et al. Small-molecule suppressors of cytokine-induced ß-cell apoptosis. ACS Chem. Biol. 5, 729-734 (2010).
105. Chou, D. H. et al. Synthesis of a novel suppressor of beta-cell apoptosis via diversity-oriented synthesis. ACS Med. Chem. Lett. 2, 698-702 (2011).
106. Scully, S. S. et al. Small-molecule inhibitors of cytokine-mediated STAT1 signal transduction in ß-cells with improved aqueous solubility. J. Med. Chem. 56, 4125-4129 (2013).
107. Eizirik, D. L., Cardozo, A. K. & Cnop, M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr. Rev. 29, 42-61 (2008).
108. Wang, H., Kouri, G. & Wollheim, C. B. ER stress and SREBP-1 activation are implicated in ß-cell glucolipotoxicity. J. Cell Sci. 118, 3905-3915 (2005).
109. Poitout, V. & Robertson, R. P. Glucolipotoxicity: fuel excess and ß-cell dysfunction. Endocr. Rev. 29, 351-366 (2008).
110. Rhodes, C. J. Type 2 diabetes-a matter of ß-cell life and death? Science 307, 380-384 (2005).
111. Robertson, R. P., Harmon, J., Tran, P. O. & Poitout, V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53 (Suppl. 1), 119-124 (2004).
112. Hotamisligil, G. S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140, 900-917 (2010).
113. Mussmann, R. et al. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J. Biol. Chem. 282, 12030-12037 (2007).
114. Stukenbrock, H. et al. 9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic ß cell protection and replication. J. Med. Chem. 51, 2196-2207 (2008).
115. Wagman, A. S., Johnson, K. W. & Bussiere, D. E. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr. Pharm. Des. 10, 1105-1137 (2004).
116. Lablanche, S. et al. Protection of pancreatic INS-1 ß-cells from glucose-and fructose-induced cell death by inhibiting mitochondrial permeability transition with cyclosporin A or metformin. Cell Death Dis. 2, e134 (2011).
117. Cnop, M., Hannaert, J. C. & Pipeleers, D. G. Troglitazone does not protect rat pancreatic ß cells against free fatty acid-induced cytotoxicity. Biochem. Pharmacol. 63, 1281-1285 (2002).
118. Finegood, D. T. et al. ß-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50, 1021-1029 (2001).
119. Han, S. J. et al. Rosiglitazone inhibits early stage of glucolipotoxicity-induced beta-cell apoptosis. Horm. Res. 70, 165-173 (2008).
120. Higa, M. et al. Troglitazone prevents mitochondrial alterations, ß cell destruction, and diabetes in obese prediabetic rats. Proc. Natl Acad. Sci. USA 96, 11513-11518 (1999).
121. Shimabukuro, M., Zhou, Y. T., Lee, Y. & Unger, R. H. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J. Biol. Chem. 273, 3547-3550 (1998).
122. Weir, G. C., Cavelti-Weder, C. & Bonner-Weir, S. Stem cell approaches for diabetes: towards beta cell replacement. Genome Med. 3, 61 (2011).
123. Chen, S. et al. A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nature Chem. Biol. 5, 258-265 (2009).
124. Tang, D. Q. et al. In vitro generation of functional insulin-producing cells from human bone marrowderived stem cells, but long-term culture running risk of malignant transformation. Am. J. Stem Cells 1, 114-127 (2012).
125. Wang, Q. et al. Reprogramming of bone marrowderived mesenchymal stem cells into functional insulin-producing cells by chemical regimen. Am. J. Stem Cells 1, 128-137 (2012).
126. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006).
127. Hou, P. et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 341, 651-654 (2013).
128. Kroon, E. et al. Pancreatic endoderm derived from human embryonic stem cells generates glucoseresponsive insulin-secreting cells in vivo. Nature Biotech. 26, 443-452 (2008).
129. Schulz, T. C. et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS ONE 7, e37004 (2012).
130. Wagner, B. K. Grand challenge commentary: chemical transdifferentiation and regenerative medicine. Nature Chem. Biol. 6, 877-879 (2010).
131. Spijker, H. S. et al. Conversion of mature human ß-cells into glucagon-producing a-cells. Diabetes 62, 2471-2480 (2013).
132. Bramswig, N. C. et al. Epigenomic plasticity enables human pancreatic a to ß cell reprogramming. J. Clin. Invest. 123, 1275-1284 (2013).
133. Dorrell, C. et al. Isolation of mouse pancreatic alpha, beta, duct and acinar populations with cell surface markers. Mol. Cell Endocrinol. 339, 144-150 (2011).
134. Dorrell, C. et al. Transcriptomes of the major human pancreatic cell types. Diabetologia 54, 2832-2844 (2011).
135. Collombat, P. et al. Opposing actions of Arx and Pax4 in endocrine pancreas development. Genes Dev. 17, 2591-2603 (2003).
136. Al-Hasani, K. et al. Adult duct-lining cells can reprogram into ß-like cells able to counter repeated cycles of toxin-induced diabetes. Dev. Cell 26, 86-100 (2013).
137. Yang, Y. P., Thorel, F., Boyer, D. F., Herrera, P. L. & Wright, C. V. Context-specific a-to-ß-cell reprogramming by forced Pdx1 expression. Genes Dev. 25, 1680-1685 (2011).
138. Thorel, F. et al. Conversion of adult pancreatic a-cells to ß-cells after extreme ß-cell loss. Nature 464, 1149-1154 (2010).
139. Xu, X. et al. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 132, 197-207 (2008).
140. Swales, N. et al. Plasticity of adult human pancreatic duct cells by neurogenin3-mediated reprogramming. PLoS ONE 7, e37055 (2012).
141. Kim, H. S. et al. Activin A, exendin-4, and glucose stimulate differentiation of human pancreatic ductal cells. J. Endocrinol. 217, 241-252 (2013).
142. Akinci, E., Banga, A., Greder, L. V., Dutton, J. R. & Slack, J. M. Reprogramming of pancreatic exocrine cells towards a beta (ß) cell character using Pdx1, Ngn3 and MafA. Biochem. J. 442, 539-550 (2012).
143. Stumvoll, M., Goldstein, B. J. & van Haeften, T. W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365, 1333-1346 (2005).
144. Barnett, A. H. et al. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int. J. Clin. Pract. 64, 1121-1129 (2010).
145. Bolen, S. et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann. Intern. Med. 147, 386-399 (2007).
146. Matschinsky, F. M. & Ellerman, J. E. Metabolism of glucose in the islets of Langerhans. J. Biol. Chem. 243, 2730-2736 (1968).
147. Matschinsky, F. M. Assessing the potential of glucokinase activators in diabetes therapy. Nature Rev. Drug Discov. 8, 399-416 (2009).
148. Matschinsky, F. M. et al. Glucokinase activators for diabetes therapy: May 2010 status report. Diabetes Care 34 (Suppl. 2), 236-243 (2011).
149. Rees, M. G. & Gloyn, A. L. Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour? Br. J. Pharmacol. 168, 335-338 (2013).
150. Briscoe, C. P. et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br. J. Pharmacol. 148, 619-628 (2006).
151. Ahren, B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nature Rev. Drug Discov. 8, 369-385 (2009).
152. Burant, C. F. et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379, 1403-1411 (2012).
153. Morris, A. P. et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nature Genet. 44, 981-990 (2012).
154. Saxena, R. et al. Large-scale gene-centric metaanalysis across 39 studies identifies type 2 diabetes loci. Am. J. Hum. Genet. 90, 410-425 (2012).
155. Zeggini, E. et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature Genet. 40, 638-645 (2008).
156. Billings, L. K. & Florez, J. C. The genetics of type 2 diabetes: what have we learned from GWAS? Ann. NY Acad. Sci. 1212, 59-77 (2010).
157. Florez, J. C. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia 51, 1100-1110 (2008).
158. Voight, B. F. et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nature Genet. 42, 579-589 (2010).
159. Wijesekara, N. et al. Beta cell-specific Znt8 deletion in mice causes marked defects in insulin processing, crystallisation and secretion. Diabetologia 53, 1656-1668 (2010).
160. Tamaki, M. et al. The diabetes-susceptible gene SLC30A8/ZnT8 regulates hepatic insulin clearance. J. Clin. Invest. 123, 4513-4524 (2013).
161. Nicolson, T. J. et al. Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetesassociated variants. Diabetes 58, 2070-2083 (2009).
162. Saxena, R. et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316, 1331-1336 (2007).
163. Zeggini, E. et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316, 1336-1341 (2007).
164. Scott, L. J. et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316, 1341-1345 (2007).
165. Wei, F. Y. et al. Deficit of tRNALys modification by Cdkal1 causes the development of type 2 diabetes in mice. J. Clin. Invest. 121, 3598-3608 (2011).
166. Wu, W. et al. Identification of glucose-dependant insulin secretion targets in pancreatic ß cells by combining defined-mechanism compound library screening and siRNA gene silencing. J. Biomol. Screen. 13, 128-134 (2008).
167. Lee, J. A. et al. Open innovation for phenotypic drug discovery: the PD2 assay panel. J. Biomol. Screen. 16, 588-602 (2011).
168. Ku, G. M., Pappalardo, Z., Luo, C. C., German, M. S. & McManus, M. T. An siRNA screen in pancreatic beta cells reveals a role for Gpr27 in insulin production. PLoS Genet. 8, e1002449 (2012).
169. Hill, J. A. et al. A multi-parameter, high-content, high-throughput screening platform to identify natural compounds that modulate insulin and Pdx1 expression. PLoS ONE 5, e12958 (2010).
170. Kalisky, T., Blainey, P. & Quake, S. R. Genomic analysis at the single-cell level. Annu. Rev. Genet. 45, 431-445 (2011).
171. Tang, F., Lao, K. & Surani, M. A. Development and applications of single-cell transcriptome analysis. Nature Methods 8, S6-11 (2011).
172. Segal, D. J. & Meckler, J. F. Genome engineering at the dawn of the golden age. Annu. Rev. Genom. Hum. Genet. 14, 135-158 (2013).
173. Ravassard, P. et al. A genetically engineered human pancreatic ß cell line exhibiting glucose-inducible insulin secretion. J. Clin. Invest. 121, 3589-3597 (2011).
174. Holliday, N. D., Watson, S. J. & Brown, A. J. Drug discovery opportunities and challenges at G protein coupled receptors for long chain free fatty acids. Front. Endocrinol. 2, 112 (2011).
175. Martinez, A., Castro, A., Dorronsoro, I. & Alonso, M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 22, 373-384 (2002).
176. Santin, I. et al. PTPN2, a candidate gene for type 1 diabetes, modulates pancreatic ß-cell apoptosis via regulation of the BH3-only protein Bim. Diabetes 60, 3279-3288 (2011).
177. Yuan, Y. et al. A small-molecule inducer of PDX1 expression identified by high-throughput screening. Chem. Biol. 20, 1513-1522 (2013).